India Imposes 30 Percent Margin Cap on Non-Scheduled Cancer Drug Prices

The Indian government has announced a 30 percent margin cap on the maximum retail price of non-scheduled anti-cancer drugs. The policy, detailed by the Department of Pharmaceuticals, is expected to save cancer patients around 258.7 million USD per year. An expert committee will finalize the list of covered medicines, after which the National Pharmaceutical Pricing Authority will issue a formal notification. Price mark-ups on non-scheduled cancer drugs were found to average around 170 percent, with some cases exceeding 700 percent.

A 30 percent ceiling on margins relative to the maximum retail price was put in place by the government, responding to longstanding concerns that anti-cancer medicines had been priced beyond the reach of many patients. Under the proposed measure, cancer medications not listed on the approved schedule would face a spending ceiling. Cancer medicines listed on the scheduled formulary had their maximum allowable prices fixed under regulatory controls. A formal release from the Department of Pharmaceuticals, operating under the Federal Ministry of Chemicals and Fertilizers, put the projected annual benefit to cancer patients at roughly 25 billion Indian Rupees — equivalent to approximately 258.7 million U.S. dollars — each year. Under the ministry's plan, an expert panel operating within the Directorate General of Health Services would draw up the roster of medicines eligible for coverage, with the National Pharmaceutical Pricing Authority then stepping in to review that roster and publish a formal notification. Data collected on non-scheduled anti-cancer treatments revealed that retail pricing routinely ran to roughly 170 percent above the base cost on average, with certain products commanding mark-ups that climbed to 700 percent or beyond. According to the statement, costs accumulated at each stage of the distribution network, leaving patients to absorb a notably higher price by the time the medicine arrived in their hands.

India Imposes 30 Percent Margin Cap on Non-Scheduled Cancer Drug Prices

Related Posts

India Imposes 30 Percent Margin Cap on Non-Scheduled Cancer Drug Prices

Related Posts